Pds Biotechnology CORP 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
NASDAQ
PDS Biotechnology Corporation reported a reduced net loss for Q3 2025, advanced multiple immunotherapy clinical trials, but raised substantial doubt about its ability to continue as a going concern.
NASDAQ
PDS Biotechnology reported an increased net loss for Q2 2025 and a going concern warning, despite advancing its immunotherapy pipeline with positive clinical trial data and new financing.
NASDAQ
10-Q: PDS Biotechnology Reports Q1 2025 Results, Highlights Clinical Trial Progress and Financial Position
PDS Biotechnology Corporation announces its financial results for the first quarter of 2025, detailing ongoing clinical trials and recent financing activities.
NASDAQ
10-Q: PDS Biotechnology Reports Third Quarter 2024 Financial Results and Provides Clinical Pipeline Update
PDS Biotechnology reported a net loss of $10.7 million for the third quarter of 2024, while continuing to advance its clinical programs.
NASDAQ
PDS Biotechnology Corp. reports a net loss of $8.3 million for the second quarter of 2024, while highlighting progress in its clinical trials and pipeline development.
NASDAQ
PDS Biotechnology reported a net loss of $10.6 million for the first quarter of 2024, while highlighting progress in its clinical trials and pipeline development.